Vistagen Therapeutics, Inc. 8-K

What Happened
Vistagen Therapeutics, Inc. filed a Form 8-K on March 18, 2026 (Item 5.02) reporting that director Mary Rotunno submitted her resignation from the company’s Board of Directors on March 17, 2026, effective April 1, 2026. The filing was signed by Shawn K. Singh, President and Chief Executive Officer.

Key Details

• Resignation submitted: March 17, 2026.
• Effective date of resignation: April 1, 2026.
• 8-K filing date: March 18, 2026 (reported under Item 5.02: Departure/Election of Directors).
• The filing does not disclose a reason for the resignation or the appointment of a replacement; it was signed by CEO Shawn K. Singh.

Why It Matters
A board member’s departure is a governance event investors watch because it can affect board composition, oversight and committee memberships. This filing provides the timing of the change but includes no explanation or successor information; investors should monitor future SEC filings or company announcements for any replacement or related governance updates. This 8-K does not include financial results or other operational disclosures.